Controversial biotech Galena Biopharma (GALE) will report Q4 and 2013 results after today's close.
Consensus estimates for the quarter are a loss of $0.09/share on revenues of $1.6M. Estimates for the year are a loss of $0.41/share on revenues of $2.7M.
Consensus views for 2014 are a loss of $0.36/share on revenues of $12.6M.
96 mutual funds have positions, up from 27 a year earlier.
Shares are up 7% premarket.